IDEA Collider: Innovation & Asymmetric Learning in Pharma

ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.

In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senio

AI-Driven Pharma Market Research: Synthetic Users - with Kwame Ferreira & Rebecca Gould.

Welcome back to the IDEA Collider podcast. In this episode, host Rick Ritacco sits down with Kwame Ferreira, Founder of Synthetic Users, and Rebecca Gould, President, Str

The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution: Part II

Welcome back to the IDEA Collider podcast. In this second instalment of our future of immuno-oncology series, Alex Gray is joined by colleagues David Radwaner and Tom Bro

Targeting the Totality of MS: Jason Tardio on Immunic’s Combined Neuroprotective and Anti-Inflammatory Strategy

Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving lands

The Future of Psychedelic Medicine: Clinical Strategy and Scaling Access.

Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psyc

The Power of the Early Narrative: Sue Wood on Strategic Biotech Positioning

Welcome to IDEA Collider with your host, Rick Ritacco.  In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of

The Execution Problem: Alex Gray and Jacqueline Poot on Pharma Decision Intelligence.

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of S

The Keytruda Blueprint: Alex Gray, David Radwaner, and Tom Brockbank on the IO Revolution

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and futur

Scaling TCR-T Therapies: Reagan Jarvis on Non-Viral Gene Editing and Target Mapping

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the

Vir Biotechnology: Marianne De Backer on Immuno-Oncology, Hepatitis Delta, and Biotech Turnarounds

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most compl

Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi

In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to

AI & Competitive Intelligence in Pharma: Smarter Decision-Making with SAI MedPartners

In this episode of the IDEA Collider podcast, industry experts explore the evolving role of AI in Competitive Intelligence (CI) in pharmaceutical and biotech strategy — a

Rewriting the Future of Rare Disease: Engineered tRNA and a New Therapeutic Paradigm with Michelle Werner

In this episode of IDEA Collider, host Mike Rea sits down with Michelle Werner, CEO of Alltrna, to explore a groundbreaking approach that could transform how we treat tho

Revitalizing Pharma Collaborations: The Reblozyl Case Study

In this episode of IDEA Collider, hosts Mike and Rick revisit a pivotal project from over a decade ago, the Reblozyl project, undertaken in collaboration with Acceleron a

Pioneering the Future of Cardiovascular Treatment with Sekar Kathiresan

In this episode of IDEA Collider, host Mike Rea speaks with Dr. Sekar Kathiresan, founder of Verve Therapeutics and now part of Eli Lilly, about one of the boldest ideas

Biotech Innovations and AI in Drug Development with Alex Telford:

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke

Dr. Christian Rommel on Oncology Innovations and Modern Drug Development at Bayer

In this episode of Idea Collider, host Mike Rea interviews Dr. Christian Rommel from Bayer. Dr. Rommel discusses his journey in molecular oncology from the Max Planck Ins

Bold Science, Bigger Bets: Mathai Mammen on Visionary R&D and Transforming Biopharma

In this insightful episode of IDEA Collider, Mike welcomes Mathai Mammen, Chairman and CEO of Parabilis Medicines. Mathai shares his extensive journey through academia, M

Bridging Clinical Practice and Biotech: Paul Peter Tak's Transformative Journey

In this episode of Idea Collider, host Mike Rea interviews Paul Peter Tak, CEO of Candel Therapeutics, discussing his remarkable journey from a clinician in Amsterdam to

Creating Breakthroughs in Oncology: A Conversation with Susan Galbraith of AstraZeneca

In this episode of Idea Collider, we sit down with Susan Galbraith from AstraZeneca, a leading figure in oncology R&D. Susan shares her journey from medical training in M